Highlights in Advanced Non–Small Cell Lung Cancer From ESMO 2022

H. Jack West, MD


October 05, 2022

Highlights in advanced non–small lung cancer (NSCLC) from the 2022 European Society for Medical Oncology Congress are presented by Dr Jack West of City of Hope Comprehensive Cancer Center in Duarte, California.

Dr West begins by discussing CodeBreak 200, a study comparing sotorasib with docetaxel in previously treated patients with a KRAS G12C mutation. Sotorasib improved progression-free survival, but overall survival data are awaited.

Next, Dr West examines 5-year updates from KEYNOTE-189 and KEYNOTE-407, comparing pembrolizumab with chemotherapy in nonsquamous and squamous disease, respectively. Around two fifths of patients remained alive and disease-free 5 years after stopping treatment.

Dr West then reports on the IPSOS trial, which compared atezolizumab with single-agent chemotherapy in patients who were ineligible for standard chemotherapy. The results suggested that immunotherapy could be used in patients who are usually excluded from trials.

He finishes with two studies in EGFR-mutated disease. ORIENT-3 indicated that the effect of sintilimab could be boosted with a bevacizumab biosimilar. INSIGHT 2 suggested that adding tepotinib to osimertinib may be effective in patients with MET amplification.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.